On Jan. 25, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics an agreement worth up to $39 million, that support the U.S. Government’s effort to enhance its rapid response capabilities for biologics medical countermeasures

Under the agreement, the DOD will have access to pivotal manufacturing capacity for anti-SARS-CoV-2 mAbs and priority access to future biomanufacturing capacity over a period of seven years in to-be-completed J.POD facility in Redmond, Washington.